KEYNOTE-905 Paves the Way for Next Generation of MIBC Trials - report from ESMO 2025

Professor Christof Vulsteke shares her thoughts on the data from the phase 3 KEYNOTE-905 trial were presented at the ESMO Congress 2025. A treatment regimen consisting of neoadjuvant enfortumab vedotin-ejfv plus pembrolizumab, radical cystectomy plus pelvic lymph node dissection, and adjuvant EV plus pembrolizumab yielded significant improvements in multiple outcomes in patients with muscle-invasive bladder cancer who are ineligible for or decline cisplatin-based chemotherapy.Video: https://medicaldigest.org/scientific-contents/interview:keynote-905-paves-way-next-generation-mibc-trials